Viridian Therapeutics (VRDN) Stock Forecast & Price Target

$19.03 +0.30 (+1.60%)

(As of 12/20/2024 05:31 PM ET)

Viridian Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
3

Buy
9

Based on 12 Wall Street analysts who have issued ratings for Viridian Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 3 have given a hold rating, and 9 have given a buy rating for VRDN.

Consensus Price Target

$35.70
87.60% Upside

According to the 12 analysts' twelve-month price targets for Viridian Therapeutics, the average price target is $35.70. The highest price target for VRDN is $61.00, while the lowest price target for VRDN is $20.00. The average price target represents a forecasted upside of 87.60% from the current price of $19.03.

Get the Latest News and Ratings for VRDN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Viridian Therapeutics and its competitors.

VRDN Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$35.70	$36.33	$35.30	$39.08
Forecasted Upside	87.60% Upside	79.87% Upside	67.14% Upside	74.01% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Your bank is lying to you. (Ad)

You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.

View the best savings account rates here

VRDN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRDN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Viridian Therapeutics Stock vs. The Competition

Type	Viridian Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	87.60% Upside	25,828.18% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent VRDN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/19/2024	Wells Fargo & Company 3 of 5 stars	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$37.00 ➝ $27.00	+42.63%
12/17/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$44.00 ➝ $47.00	+132.44%
12/16/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$34.00 ➝ $34.00	+49.12%
11/25/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00	+88.12%
11/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Thome Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
9/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$56.00 ➝ $61.00	+162.37%
Could This Tiny Device Help You Make an Extra $30k a Year? (Ad) I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich.
9/12/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$25.00 ➝ $31.00	+43.45%
8/12/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $28.00	+86.92%
7/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$42.00 ➝ $42.00	+145.61%
6/11/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$29.00	+137.32%
5/9/2024	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Higgins Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/9/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Patel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$25.00 ➝ $20.00	+34.23%
11/14/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$42.00 ➝ $38.00	+152.16%
9/13/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$40.00	+140.10%
1/9/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$40.00 ➝ $45.00	+41.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:30 AM ET.

VRDN Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Viridian Therapeutics is $35.70, with a high forecast of $61.00 and a low forecast of $20.00.
: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VRDN shares.
: According to analysts, Viridian Therapeutics's stock has a predicted upside of 87.60% based on their 12-month stock forecasts.
: Viridian Therapeutics has been rated by research analysts at BTIG Research, HC Wainwright, Needham & Company LLC, Royal Bank of Canada, TD Cowen, and Wells Fargo & Company in the past 90 days.
: Analysts like Viridian Therapeutics less than other "medical" companies. The consensus rating score for Viridian Therapeutics is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how VRDN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

This page (NASDAQ:VRDN) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Stock Forecast & Price Target